3-(二甲基氨基)丙基乙酸酯 | 4339-94-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-(二甲基氨基)丙基乙酸酯
• 英文名称: 3-(dimethylamino)-1-propyl acetate
• 英文别名: acetic acid-(3-dimethylamino-propyl ester)；Essigsaeure-(3-dimethylamino-propylester)；1-Acetoxy-3-dimethylamino-propan；Dimethyl-(3-acetoxy-propyl)-amin；3-(Dimethylamino)propyl acetate
• CAS: 4339-94-0
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: QIOHHDBZBVJGCT-UHFFFAOYSA-N

物化性质

• 沸点：
  176.5±23.0 °C(Predicted)
• 密度：
  0.937±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(二甲基氨基)丙基乙酸酯 在 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 二氯甲烷 为溶剂， 反应 0.68h， 生成 3-(Dimethylamino)propyl 3-[bis[bis(2-chloroethyl)amino]phosphanyloxy]-3-(4-nitrophenyl)propanoate
  参考文献：
  名称：

  Nitrobenzyl Phosphorodiamidates as Potential Hypoxia-Selective Alkylating Agents

  摘要：

  A series of novel nitrobenzyltetrakis(chloroethyl)phosphorodiamidates has been prepared, and its cytotoxicity has been evaluated against HT-29 cells under aerobic and hypoxic conditions and against murine bone marrow progenitor cells under aerobic conditions. All compounds were selectively toxic to HT-29 cells under hypoxic conditions, and the selectivity ratios varied from 1.6 to >90. Analogs lacking either the nitro group or the tetrakis(chloroethyl) moiety were not cytotoxic, confirming that the presence of both nitro and incipient alkylating groups are essential for activity. Surprisingly, some analogs were far more toxic to bone marrow progenitors than to HT-29 cells under aerobic conditions, suggesting that other activation mechanisms must exist in these hematopoietic cells. Cytotoxicity increased with increasing depth in the HT-29 spheroid model, consistent with the preferential hypoxic toxicity of these compounds. Alkaline elution experiments showed a greater number of DNA interstrand cross-links under hypoxic compared to aerobic conditions. The extent of cross-linking in hypoxic cells was essentially identical to that produced by an equitoxic dose of melphalan, suggesting that the cytotoxicity of these compounds results from phosphorodiamidate release and alkylation of DNA.

  DOI：

  10.1021/jm00037a011
• 作为产物：
  描述：

  3-二甲氨基-1-丙醇 、 4-硝基苯基乙酸酯 以 乙腈 为溶剂， 生成 3-(二甲基氨基)丙基乙酸酯
  参考文献：
  名称：

  The influence of anchoring substitution in 1,3-amino alcohols on the rate and mechanism of esterification by acetylimidazole and by p-nitrophenyl acetate

  摘要：

  对硝基苯乙酸酯和 1-乙酰基咪唑在乙腈中的竞争性醇解以及相应的二阶速率常数和活化参数表明，2-叔丁基-3-(NN-二甲基氨基)丙-1-醇中的强制分子内氢键对催化酰基转移的速率和机理都有影响。

  DOI：

  10.1039/c39930000294

文献信息

• [EN] NUCLEIC ACID CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS DE TYPE ACIDE NUCLÉIQUE ET LEURS UTILISATIONS
  申请人：TRANSLATE BIO MA INC

  公开号：WO2018013525A1

  公开（公告）日：2018-01-18

  Provided herein are conjugates comprising targeting moieties such as sugars, folates and cell-penetrating peptides, which can be used for the improved delivery of agents (e.g., nucleic acids, such as oligonucleotides or mRNAs, or other agents) to cells. The invention provides conjugates and compounds comprising targeting moieties, methods for preparing the same, and intermediates useful in their preparation. In another aspect, the present invention provides formulations (e.g., pharmaceutical compositions) comprising the targetting moiety-containing conjugates and compounds. The present invention also provides methods for delivering agents (e.g., nucleic acids such as oligonucleotides or mRNAs) to a cell, methods for treating and/or preventing a disease or condition in a subject, and methods for modulating gene expression in a cell or a subject. Further, provided herein are kits comprising the conjugates, or formulations thereof; and kits for the preparation of conjugates described herein.

  本文提供了包含靶向基团的共轭物，如糖类、叶酸和穿膜肽，可用于改善药物（例如核酸，如寡核苷酸或mRNA，或其他药物）对细胞的传递。该发明提供了包含靶向基团的共轭物和化合物，以及其制备方法和制备过程中有用的中间体。另一方面，本发明提供了包含靶向基团的共轭物和化合物的配方（例如，药物组合物）。本发明还提供了将药物（例如核酸，如寡核苷酸或mRNA）传递至细胞的方法，用于治疗和/或预防受试者疾病或状况的方法，以及用于调节细胞或受试者基因表达的方法。此外，本文提供了包含这些共轭物或其配方的试剂盒；以及用于制备本文所述共轭物的试剂盒。
• [EN] LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE<br/>[FR] ADMINISTRATION LIPIDIQUE D'AGENTS THÉRAPEUTIQUES AU TISSU ADIPEUX
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2018191719A1

  公开（公告）日：2018-10-18

  A method of treating a disease mediated by protein expression in adipose tissue by intraperitoneally administering a composition comprising a lipid nanoparticle encapsulating or associated with a therapeutic agent (e.g., a nucleic acid), thereby delivering the therapeutic agent to adipose tissue of the subject and altering protein expression in the adipose tissue is provided herein. A method for delivering a therapeutic agent to adipose tissue of a subject in need thereof is also provided.

  本发明提供了一种治疗由脂肪组织中蛋白质表达介导的疾病的方法，通过腹膜内给药一种包含脂质纳米粒的制剂，该脂质纳米粒封装或与治疗剂（例如，核酸）相关联，从而将治疗剂递送到受试者的脂肪组织并改变脂肪组织中的蛋白质表达。本发明还提供了一种将治疗剂递送到需要治疗的受试者脂肪组织的方法。
• [EN] BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS<br/>[FR] LIPIDES BIODÉGRADABLES POUR L'ADMINISTRATION D'AGENTS ACTIFS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2013086354A1

  公开（公告）日：2013-06-13

  The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及一种阳离子脂质，其中在阳离子脂质的脂质部分（例如，疏水链）中具有一个或多个可生物降解的基团。这些阳离子脂质可以掺入脂质粒子中，用于递送一种活性剂，例如核酸。本发明还涉及包含中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选的甾醇的脂质粒子。脂质粒子还可以进一步包括治疗剂，例如核酸。
• Mechanism of esterification of 1,3-dimethylamino alcohols by N-acetylimidazole in acetonitrile and the influence of alkyl and geminal dialkyl substitution upon the rate
  作者：Annemieke Madder、Sonny Sebastian、Dirk Van Haver、Pierre J. De Clercq、Howard Maskill

  DOI：10.1039/a608488e

  日期：——

  catalysed formation of a cyclic tetrahedral intermediate. Effective molarities compared with the third-order reactions of simpler alcohols with acetylimidazole catalysed by triethylamine are estimated to be 13–14 mol dm–3, but alkyl substitution at the 2-position of the amino alcohol has only a modest effect upon reaction rates. All reactions have substantial negative entropies of activation and only modest

  通过常规方法制备了3-（二甲基氨基）丙-1-醇和七个在2-位具有烷基取代基的衍生物，并在拟第一个条件下测定了N-乙酰基咪唑在乙腈中酯化的二阶速率常数。在单一温度（23°C）下通过1 H NMR光谱法和在25–65°C的温度范围内通过UV光谱法测定有序条件。证据表明，分子间酯化反应是通过确定分子速率的分子内一般碱催化环状四面体中间体的形成而进行的。与简单醇与三乙胺催化的乙酰咪唑的三阶反应相比，有效摩尔数估计为13–14 mol dm–3，但氨基醇2位上的烷基取代对反应速率的影响很小。所有反应均具有基本负的活化熵，并且只有适度的活化焓，这是具有高度有序过渡结构的协同双分子反应所期望的。三种结构相关的碳环氨基醇组成一个短的等速序列，其等速温度非常接近实验范围。在这个系列中，越来越少的激活熵对激活焓降低了几乎完全平衡，它们对室温附近的总激活自由能的贡献。
• [EN] BRANCHED ALKYL AND CYCLOALKYL TERMINATED BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS<br/>[FR] LIPIDES BIODÉGRADABLES RAMIFIÉS À TERMINAISONS ALKYLE ET CYCLOALKYLE DESTINÉS À L'ADMINISTRATION D'AGENTS ACTIFS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2013086322A1

  公开（公告）日：2013-06-13

  The present invention relates to a cationic lipid of formula (I) having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

  本发明涉及具有一个或多个生物可降解基团的阳离子脂质的化学式(I)，所述生物可降解基团位于阳离子脂质的脂质部分（例如，疏水链）中。这些阳离子脂质可以被纳入脂质粒子中，用于传递活性剂，例如核酸。该发明还涉及包括中性脂质、能够减少聚集的脂质、本发明的阳离子脂质以及可选地固醇的脂质粒子。脂质粒子还可以进一步包括治疗剂，例如核酸。